Wood, Kristy M.

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine

Amyloidosis: Diagnosis, Treatment, OutcomesLysosomal Storage Disorders Research

Cited by 1,766

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

Finn, J. D., Smith, A. R., Patel, M. C., Shaw, L., Youniss, M. R., van Heteren, J., Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., et al. (2018) · Cell Reports

RNA Interference and Gene DeliveryCRISPR and Genetic Engineering

Cited by 878

Hydrogels for oral delivery of therapeutic proteins

Peppas, N. A., Wood, K. M., & Blanchette, J. O. (2004) · Expert Opinion on Biological Therapy

Hydrogels: synthesis, properties, applicationsAdvanced Drug Delivery Systems

Cited by 161

Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich’s ataxia

Nabhan, J. F., Wood, K. M., Rao, V. P., Morin, J., Bhamidipaty, S., LaBranche, T. P., Gooch, R. L., Bozal, F., Bulawa, C. E., & Guild, B. C. (2016) · Scientific Reports

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 140